



**Sterne Kessler
Goldstein Fox**
ATTORNEYS AT LAW

Robert Greene Sterne
George A. Goldstein
David K.S. Cornwell
Robert W. Conrad
Tacy-Gene G. Durkin
Michelle A. Garbala
Michael B. Ray
Robert E. Scholtz
Eric K. Tarlo
Michael Q. Lee
John M. Covert
Robert C. Millington
Donald J. Featherstone
Timothy J. Shaw, Jr.
Michael V. Messenger
Justin U. Kim
Jeffrey I. Huey
Eldora L. Ellison

Donald R. Bancroft
Peter A. Jackson
Brian J. Del Buono
Mark Fox Evans
Vincent L. Capuano
Elizabeth J. Haines
Michael D. Specht
Kevin W. McCabe
Glen J. Perry
Edward W. Yee
Grant E. Reed
Vigil Lee Boston
Theodore A. Wood
Joseph S. Doroff
Jason D. Eisenberg
Kacy L. Muller
Jon L. Wright
LuAnne M. DeSantis

Ann E. Sumnerfield
Helene C. Carlson
Cynthia M. Boucher
Timothy A. Doyle
Gabry L. Longworth
Lori A. Gordon
Laura A. Vogel
Bryan S. Wade
Basil M.S. Ali
Shannon A. Carroll
Arthur F. Khal
Michelle K. Holoubek
Marsha A. Rose
Scott A. Schuller
Lei Zhou
W. Blake Cobbentz
James J. Foll
John T. Haman

Mark W. Bygiel
Michael R. Waletz
Carla J-Eun Kim
Dorey A. Soper
Ulrike Winkler Jenks
Paul A. Calvo
Robert A. Schwartzman
C. Matthew Rozer
Shameek Ghose
Randall K. Baldwin
Daniel J. Newby
Registered Patent Agents
Karin B. Markowicz
Matthew J. Dowd
Mita Matherne
Scott M. Woodhouse
Peter A. Socrates

Jeffrey K. Mills
Danielle L. Letting
Lori Brandes
Steven C. Oppenheimer
Aaron S. Lukas
Gaurav Asthana

(Of Counsel)
Edward J. Kessler
Kenneth C. Bass III
Marvin C. Guthrie
Christopher P. Winst

*Admitted only in Maryland
*Admitted only in Virginia
•Practice limited to Federal Agencies

October 22, 2007

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

WRITER'S DIRECT NUMBER:
(202) 772-8679
INTERNET ADDRESS:
TSHEA@SKGF.COM

Art Unit 1636

Re: U.S. Utility Patent Application
Application No. 10/633,697; Filed: August 5, 2003
For: **Glycosylation Engineering of Antibodies for Improving Antibody-
Dependent Cellular Cytotoxicity**
Inventors: UMANA *et al.*
Our Ref: 1975.0010005/TJS

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Request for Continued Examination (RCE) Transmittal;
2. Amendment and Reply Under 37 C.F.R. §1.111 and §1.114;
3. Terminal Disclaimer to Obviate a Provisional Double Patenting Rejection Over a Pending "Reference" Application;
4. Terminal Disclaimer to Obviate a Double Patenting Rejection Over a "Prior" Patent;
5. Statement Under 37 CFR §3.73(b);
6. Power of Attorney to Prosecute Applications;
7. Second Supplemental Information Disclosure Statement;
8. Form PTO/SB/08A (1 sheet) listing 10 documents (AA2 to AE2 and AL2 to AP2);
9. Form PTO/SB/08B (3 sheets) listing 23 documents (AR55 to AS62); and
10. Copies of cited documents (AL2-AP2 and AR55-AS62).

11. Online Credit Card Payment Authorization in the amount of \$1,250.00 to cover:

\$810.00 Fee for Requested for Continued Examination (RCE);

\$260.00 Fees for two Terminal Disclaimers; and

\$180.00 Fee for Second Supplemental Information Disclosure Statement.


The above-listed documents are being filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Fee payment is provided through online credit card payment. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDBSTEIN & FOX P.L.L.C.



Timothy J. Shea, Jr.

Attorney for Applicants

Registration No. 41,306

TJS/lrd
Enclosures

735126_1.DOC